In this issue:
Improved response rates in recent phase 1 US oncology trials
Deep learning algorithm streamlines NSCLC radiotherapy planning
Sintilimab/IBI305 plus chemotherapy delays EGFR-mutated NSCLC progression
No survival benefit to CT-based follow-up for resected NSCLC
High TMB improves response to checkpoint inhibition in NSCLC
Atezolizumab for pre-treated NSCLC with idiopathic interstitial pneumonia
Effectiveness and tolerability of brigatinib for NSCLC after prior ALK-TKIs
NADIM: Survival benefit to neoadjuvant chemoimmunotherapy for operable NSCLC
TMB impacts efficacy of pembrolizumab-based therapy in gastric cancer
Sequential use of pemetrexed for EGFR-mutated NSCLC extends survival
Please login below to download this issue (PDF)